Resmed Inc (RMD)

NYSE:RMD

RMD

Resmed

RESEARCH TOOLSreports

Want to see RMD full AI Analyst Report?

Resmed (RMD) Stock Forecast & Price Target

1,163 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RMD Analyst Ratings

Moderate Buy

8 Buy

5 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Resmed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RMD Stock 12 Month Forecast

Average Price Target

$286.70

▲(25.68% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Resmed in the last 3 months. The average price target is $286.70 with a high forecast of $340.00 and a low forecast of $255.00. The average price target represents a 25.68% change from the last price of $228.12.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"219":"$219","280":"$280","341":"$341","249.5":"$249.5","310.5":"$310.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":340,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$340.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":286.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$286.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":255,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$255.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[219,249.5,280,310.5,341],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,222.85,231.86153846153846,240.87307692307692,249.8846153846154,258.8961538461538,267.9076923076923,276.91923076923075,285.9307692307692,294.9423076923077,303.95384615384614,312.9653846153846,321.9769230769231,330.98846153846154,{"y":340,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,222.85,227.76153846153846,232.6730769230769,237.58461538461538,242.49615384615385,247.4076923076923,252.31923076923076,257.2307692307692,262.14230769230767,267.05384615384617,271.9653846153846,276.87692307692305,281.78846153846155,{"y":286.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,222.85,225.3230769230769,227.79615384615383,230.26923076923077,232.7423076923077,235.2153846153846,237.68846153846152,240.16153846153847,242.6346153846154,245.1076923076923,247.58076923076922,250.05384615384617,252.52692307692308,{"y":255,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":220.321,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":234.384,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.382,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":254.53,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":277.315,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":273.225,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":269.582,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.724,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":247.805,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":240.313,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":254.151,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":257.39,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.85,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$340.00

Average Price Target$286.70

Lowest Price Target$255.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

04/17/26

ResMed: Buy Rating on Depressed Valuation as Market Overprices Philips and GLP‑1 Risks

Chris Cooper

Goldman Sachs

―

Buy

―

Initiated

04/15/26

J.P. Morgan Keeps Their Buy Rating on Resmed (RMD)

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$300→$255

Buy

11.78%

Upside

Reiterated

04/13/26

ResMed price target lowered to $255 from $300 at Evercore ISIResMed price target lowered to $255 from $300 at Evercore ISI

Anthony Petrone

Mizuho Securities

$264→$255

Buy

11.78%

Upside

Reiterated

04/13/26

Mizuho Securities Sticks to Their Buy Rating for Resmed (RMD)

Laura Sutcliffe

Citi

$345→$340

Buy

49.04%

Upside

Reiterated

04/09/26

ResMed price target lowered to $340 from $345 at CitiResMed price target lowered to $340 from $345 at Citi

David Bailey

Morgan Stanley

$310

Buy

35.89%

Upside

Reiterated

03/22/26

Resmed: Strong Market Position and Financial Profile Offer Upside Amid Overstated GLP‑1 and Competitive Risks

Jonathan Block

Stifel Nicolaus

$265

Hold

16.17%

Upside

Reiterated

03/16/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Resmed (NYSE: RMD) and Scholar Rock Holding (NASDAQ: SRRK)

Adam Maeder

Piper Sandler

$270→$275

Hold

20.55%

Upside

Reiterated

01/30/26

ResMed price target raised to $275 from $270 at Piper SandlerResMed price target raised to $275 from $270 at Piper Sandler

David Rescott

Robert W. Baird

$275→$281

Hold

23.18%

Upside

Reiterated

01/30/26

ResMed price target raised to $281 from $275 at BairdResMed price target raised to $281 from $275 at Baird

Larry Biegelsen

Wells Fargo

$265→$270

Hold

18.36%

Upside

Reiterated

01/30/26

Analysts Conflicted on These Healthcare Names: Resmed (NYSE: RMD), Radiopharm Theranostics Limited Sponsored ADR (NASDAQ: RADX) and Stryker (NYSE: SYK)

Michael Matson

Needham

―

Hold

―

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: Stryker (NYSE: SYK), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Resmed (NYSE: RMD)

Mark Wilson CFA

RBC Capital

$311→$314

Buy

37.65%

Upside

Reiterated

01/30/26

RBC Capital Reaffirms Their Buy Rating on Resmed (RMD)

Brett Fishbin

KeyBanc

$302

Buy

32.39%

Upside

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD), Waters (NYSE: WAT) and Teva Pharmaceutical (NYSE: TEVA)

Lyanne Harrison

Bank of America Securities

$300

Buy

31.51%

Upside

Reiterated

01/20/26

Resmed (RMD) Receives a Buy from Bank of America Securities

Marcus Curley

UBS

$335→$345

Buy

51.24%

Upside

Reiterated

12/12/25

Analysts Offer Insights on Healthcare Companies: Insulet (NASDAQ: PODD) and Resmed (NYSE: RMD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

04/17/26

ResMed: Buy Rating on Depressed Valuation as Market Overprices Philips and GLP‑1 Risks

Chris Cooper

Goldman Sachs

―

Buy

―

Initiated

04/15/26

J.P. Morgan Keeps Their Buy Rating on Resmed (RMD)

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$300→$255

Buy

11.78%

Upside

Reiterated

04/13/26

ResMed price target lowered to $255 from $300 at Evercore ISIResMed price target lowered to $255 from $300 at Evercore ISI

Anthony Petrone

Mizuho Securities

$264→$255

Buy

11.78%

Upside

Reiterated

04/13/26

Mizuho Securities Sticks to Their Buy Rating for Resmed (RMD)

Laura Sutcliffe

Citi

$345→$340

Buy

49.04%

Upside

Reiterated

04/09/26

ResMed price target lowered to $340 from $345 at CitiResMed price target lowered to $340 from $345 at Citi

David Bailey

Morgan Stanley

$310

Buy

35.89%

Upside

Reiterated

03/22/26

Resmed: Strong Market Position and Financial Profile Offer Upside Amid Overstated GLP‑1 and Competitive Risks

Jonathan Block

Stifel Nicolaus

$265

Hold

16.17%

Upside

Reiterated

03/16/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Resmed (NYSE: RMD) and Scholar Rock Holding (NASDAQ: SRRK)

Adam Maeder

Piper Sandler

$270→$275

Hold

20.55%

Upside

Reiterated

01/30/26

ResMed price target raised to $275 from $270 at Piper SandlerResMed price target raised to $275 from $270 at Piper Sandler

David Rescott

Robert W. Baird

$275→$281

Hold

23.18%

Upside

Reiterated

01/30/26

ResMed price target raised to $281 from $275 at BairdResMed price target raised to $281 from $275 at Baird

Larry Biegelsen

Wells Fargo

$265→$270

Hold

18.36%

Upside

Reiterated

01/30/26

Analysts Conflicted on These Healthcare Names: Resmed (NYSE: RMD), Radiopharm Theranostics Limited Sponsored ADR (NASDAQ: RADX) and Stryker (NYSE: SYK)

Michael Matson

Needham

―

Hold

―

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: Stryker (NYSE: SYK), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Resmed (NYSE: RMD)

Mark Wilson CFA

RBC Capital

$311→$314

Buy

37.65%

Upside

Reiterated

01/30/26

RBC Capital Reaffirms Their Buy Rating on Resmed (RMD)

Brett Fishbin

KeyBanc

$302

Buy

32.39%

Upside

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD), Waters (NYSE: WAT) and Teva Pharmaceutical (NYSE: TEVA)

Lyanne Harrison

Bank of America Securities

$300

Buy

31.51%

Upside

Reiterated

01/20/26

Resmed (RMD) Receives a Buy from Bank of America Securities

Marcus Curley

UBS

$335→$345

Buy

51.24%

Upside

Reiterated

12/12/25

Analysts Offer Insights on Healthcare Companies: Insulet (NASDAQ: PODD) and Resmed (NYSE: RMD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Resmed

3 Months

xxx

Success Rate

6/10 ratings generated profit

Average Return

+2.60%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.60% per trade.

1 Year

Lyanne HarrisonBank of America Securities

Success Rate

17/26 ratings generated profit

Average Return

+10.25%

Copying Lyanne Harrison's trades and holding each position for 1 Year would result in 65.38% of your transactions generating a profit, with an average return of +10.25% per trade.

2 Years

xxx

Success Rate

15/26 ratings generated profit

Average Return

+13.83%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 57.69% of your transactions generating a profit, with an average return of +13.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RMD Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RMD has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. RMD average Analyst price target in the past 3 months is 286.70.

Each month's total comprises the sum of three months' worth of ratings.

RMD Financial Forecast

RMD Earnings Forecast

Next quarter’s earnings estimate for RMD is $2.80 with a range of $2.70 to $2.93. The previous quarter’s EPS was $2.81. RMD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RMD has Performed in-line its overall industry.

RMD Sales Forecast

Next quarter’s sales forecast for RMD is $1.42B with a range of $1.40B to $1.45B. The previous quarter’s sales results were $1.42B. RMD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RMD has Performed in-line its overall industry.

RMD Stock Forecast FAQ

What is RMD’s average 12-month price target, according to analysts?

Based on analyst ratings, Resmed Inc’s 12-month average price target is 286.70.

What is RMD’s upside potential, based on the analysts’ average price target?

Resmed Inc has 25.68% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RMD a Buy, Sell or Hold?

Resmed Inc has a consensus rating of Moderate Buy which is based on 8 buy ratings, 5 hold ratings and 0 sell ratings.

What is Resmed Inc’s price target?

The average price target for Resmed Inc is 286.70. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $340.00 ,the lowest forecast is $255.00. The average price target represents 25.68% Increase from the current price of $228.12.

What do analysts say about Resmed Inc?

Resmed Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of RMD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Resmed (RMD) Stock Forecast & Price Target

RMD Analyst Ratings

RMD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Resmed

RMD Analyst Recommendation Trends

RMD Financial Forecast

RMD Earnings Forecast

RMD Sales Forecast

RMD Stock Forecast FAQ

Detailed List of Analyst Forecasts